Results from a recent study that systematically analyzed the data of placebo-controlled trials in patients with BPH confirm that BPH is a progressive disease on the basis of worsening prostate volume, maximum urinary flow, and symptom score, as well as the rate of prostate-related surgery and acute urinary retention.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.